Attendee search 

Since 1989, at ferropharma we are changing the health care market by cutting value chains to decrease cost of drug development and drug availability.
One of our brand, EMELEMA® - Making Latest Medicine Available – is what we believe in and what drives the best talent from around the globe to join us.  
Our aim is to be known as the company that increases patient access to generic and innovative medicine. We focus on building bridges between markets, stakeholders and patients. Collectively, we believe in finding the most fair, straight and reliable provider for the distribution of Active Pharmaceutical Ingredients (API), Finished Dosage Forms (FDF) and services. Thanks to our dedicated teams in Brazil, China, Germany, India and Malta, we are using manufacturing plants for high quality products, in the most efficient way. We direct our attention on novel delivery systems and the provision of EU registered and manufactured drugs..
We made quality our priority. The EMA, FDA and ANVISA standards for APIs and FDFs are our benchmarks that we fulfill.
We operate worldwide but our core markets are China, Latin America and the European Union.

Pharma

TIF is a VC investor specializing in early stage biotech companies in China.

www.tsinghua-sz.org/www.leaguer.com.cn

OP Financial Limited (1140.HK) is a cross-border and cross-sector investment company that listed on the main board of the Stock Exchange of Hong Kong Limited. OP Financial has strong capability of investment, financing and industry consolidation, while its investment portfolios cover many listed and unlisted company across geographies and industries. According to the investment cycle, OP Financial builds cross-cycle portfolios with long-term core holding companies, medium-term private equity and venture capital funds and short-term arbitrage project, which are tailored to create steady returns for the shareholders.

Zhejiang Jianfeng Pharmaceutical Co., Ltd., founded on Dec. 30th, 1998, is a wholly-owned subsidiary of listed company Zhejiang Jianfeng Group Co., Ltd. (SHA: 600668). 　　Our company consists of five industrial enterprises, three commercial enterprises, three scientific institutions and two mobile postdoctoral stations. It is one of National Top 100 Pharmaceutical Enterprises, one of Top 10 Pharmaceutical Industrial Enterprises of Zhejiang Province, National Key High-tech Enterprise, National high-tech Industrialization Demonstration Project Enterprise, Innovative Demonstration Enterprise of Zhejiang Province, and AAA-level Contract-honoring and Promise-keeping Enterprise of Zhejiang Province.

Our key products include Aspartic Acid Amlodipine Tablets, Aceclofenac Sustained-release Tablets, Paroxetine Hydrochloride Tablets, Cefmenoxime Hydrochloride for Injection, Yufeng Ningxin Drop Pills, Penciclovir for Injection, Sodium Hyaluronate Eye Drops, and etc.

Adhering to the corporate spirit of “Aiming for Top One, Producing Fine Medicine”, pursuing business philosophy of “science and technology achieve health”, our company has been oriented by the development of bulk pharmaceutical chemicals with high technology content and high-added value, and new chemical medicine preparations and aided by the natural products extraction and proprietary Chinese medicine preparations. Meanwhile, our company is paying attention to the development method of new biological agent medicine, and will enter into the health product field in good time. We now have a main line with three major series products, which are anti-infection medicine, cardiovascular medicine, and anti-depression medicine. Depending on first-rate business philosophy, first-rate production management and first-rate products, our company will create a famous brand that is trusted by the public, and contribute to the health of human.

hospital